ERBB2 and breast carcinoma: Other anti-HER2 agents, including small-molecule inhibitors (lapatinib, neratinib), and ADC drugs (trastuzumab emtansine, trastuzumab deruxtecan) have also been approved for HER2-overexpression breast cancers [14–18].